Marunaka Industries Co., Ltd.
Dashboard
Decision

Maintenance-fee revision: 0% / +4% / +8%

+8% triggers Daido re-tender (R4); 0% leaves a margin gap; +4% bundled with Marunaka Care (P1) balances both.

NEURON ingested 312 items
Related risks:R4P1
Related signals:

Decision

Criterion0%+4% w/ value-add+8%
Revenue upliftNoneMediumHigh
Churn riskLowLow–MedHigh (Daido re-tender)
CompetitivenessHighMediumLow
Recommendation
+4% bundled with Marunaka Care.Med confidence

Evidence

Daido emailChurn model

Risks of each option

  • +8% → Daido re-tender (R4)
  • 0% → margin gap

Open questions

  • What value-add justifies +4% to top accounts?